

v1: 12 November 2024

Review Article

Magnesium and Longevity

Preprinted: 1 November 2024

Peer-approved: 12 November 2024

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 6 (2024)
ISSN: 2632-3834

Patrick Chambers¹

1. Torrance Memorial Medical Center, Torrance, United States

Magnesium (Mg) is not prominent among the list of well-known anti-aging agents. Yet, the signs and symptoms of aging mimic those of Mg deficiency. Mg is required for nearly a thousand enzymatic reactions. This narrative review does not correlate Mg status with clinical data on agents linked to longevity. The approach is more novel and highlights specific Mg-dependent physiologic reactions required by these longevity-linked biomarkers. Many of these share common pathways to extend healthspan. Mg is a required cofactor in the synthesis of vitamin D and melatonin and in the activation of six of the eight B vitamins. It is a required cofactor for all CYP450 enzymes. It is directly responsible for the appropriate methylation of proteins and DNA, which control the epigenome. The MTHFR (methylenetetrahydrofolate reductase) 677T allele that compromises methylation is present in a majority of Americans. Aberrant methylation predicts the severity of Covid-19 and its persistence into long Covid. Mg is a silent benefactor that may indirectly link these longevity agents, but only if viewed in context with calcium (Ca), i.e., Ca:Mg. Both compete for the same receptor. To fully exploit these longevity agents, sufficient Mg is required. The pertinent physiology is presented, although cause and effect await publication of supporting clinical data.

Correspondence: papers@team.qeios.com — Qeios will forward to the authors

1. Introduction

Optimal longevity involves extending healthspan, not just lifespan. Its pursuit has been energized by recent breakthroughs in our understanding of its pathobiology. The contribution of the gut microbiome to our general health is at the top of this list. Many elements are associated with longevity. Some are well known, e.g., high-density lipoprotein cholesterol (HDL-C), heart rate variability (HRV), vitamin D, and telomeres. Others are less well known but well documented, e.g., aryl hydrocarbon receptors (AhRs), histone deacetylase inhibitors (HDACi). There are numerous molecules associated with longevity. Popular ones include short-chain fatty acids (SCFAs), polyunsaturated fatty acids, and glucagon-like peptide-1 (GLP-1). Ozempic (semaglutide) is a GLP-1 agonist. Although well known for weight loss, it also brings longevity benefits. Almost all exhibit some connection to the gut microbiome. Many involve the epigenome and raise the question – can we control our genes to some extent by what we eat? Intake of Mg is critical. It is required as a cofactor or activator for over 800 enzymatic reactions^[1]. It is involved in over 80% of known metabolic functions^[2]. The dominance of so many Mg-dependent enzymes may in part explain why many Mg deficiency symptoms mimic those of aging^[3]. Mg deficiency has long been connected to cellular senescence^[4]. Mg potentiates each

of the discussed longevity agents, either directly or indirectly by enhancing the precursors or metabolites of their designated biopathways. Half of Americans are deficient in Mg. This figure would be much higher if the lower limit of its acceptable range were to be slightly increased to eliminate normomagnesemia Mg deficiency, as indicated by intra-erythrocytic Mg^[5], now known as chronic latent Mg deficit.

2. Discussion

I. Gut Microbiome

A healthy gut microbiome produces abundant longevity agents – secondary bile acids, indoles, and short-chain fatty acids^[6]. Each triggers the secretion of GLP-1^[7]. GLP-1 agonists are also linked to longevity^{[8][9]}, primarily because they preserve insulin sensitivity. This biomarker deteriorates with age, even in those with normal blood glucose and body weight^[10]. Insulin resistance is an early hallmark of cancer, type 2 diabetes (T2DM), and dementia (T3DM)

A. Secondary Bile Acids

Primary bile acids are normally conjugated in the liver after the hepatic degradation of cholesterol. This involves CYP450 enzymes, which are all Mg dependent^[11]. These primary bile acids must be deconjugated before gut bacteria can dehydroxylate and dehydrogenate them to produce secondary bile acids^[12]. A central pathway in the production of secondary bile acids by gut bacteria is 7-alpha dehydroxylation^[13]. 7-dehydroxylated bile acids are the most potent agonists for host bile acid receptors^[14]. The process of 7- α -dehydroxylation is enabled by 7-alpha dehydrogenase, a Mg dependent enzyme^[15]. The contribution of Mg to the production of secondary bile acids is, therefore, operating in both the liver (CYP 450 enzymes) and the intestinal lumen (7-alpha dehydrogenase).

Gilbert's syndrome, linked to longevity, is a genetic disorder characterized by an increase in unconjugated bilirubin^[16]. It is characterized by less oxidative stress, less inflammaging, a lower body mass index, a stronger vagal tone, and less risk for cardiovascular disease (CVD) or T2DM than healthy controls^[17]. The longevity benefits in Gilbert's Syndrome might be due to the fast-tracking of unconjugated primary bile acids to secondary bile acids. Unconjugated primary bile acids normally compose less than 1% of total biliary acids^[18]. Nonetheless, the production of primary bile acids is critical, and Mg deficiency compromises this. Bile acid production decreases with age^[19], as do Mg levels. Indeed, the symptoms of Mg deficiency reflect those of aging^[3].

B. Indoles

The gut microbiome also produces indole/indole derivatives, longevity agents that also trigger the release of GLP-1. Gut bacteria metabolize tryptophan, creating these indole derivatives. Downregulation of tryptophan dioxygenase (TDO) and indoleamine dioxygenase (IDO) increases tryptophan and decreases kynurenine, extending lifespan^[20] (see figure 1).




Figure 1. AhR=aryl hydrocarbon receptor, LC=long Covid, FMT=fecal microbiota transplantation, K/T=kynurenine to tryptophan, T2DM=type 2 diabetes, GLP=glucagon like peptide, NAD=nicotinamide adenine dinucleotide, red arrows, boxes => unfavorable, green arrows, boxes => favorable

Altered tryptophan metabolism (ATM) and an increased kynurenine to tryptophan ratio are hallmarks of cancer, dementia, autoimmune disease, and obesity. In each, tryptophan depletion is prominent, leaving less for indole synthesis. Indole derivative production also requires CYP 450 enzymes, all of which are Mg⁺⁺ dependent^[11]. Indoles also induce the release of GLP-1, known to suppress appetite, increase insulin secretion, and slow gastric emptying^[8]. Indoles are also ligands for aryl hydrocarbon receptors (see section IV), another longevity agent conduit.

C. Butyrate

Butyrate is another GLP-1 agonist^[21] and an aryl hydrocarbon ligand. Both are longevity indicators. Probiotics, rich in butyrogenic bacteria, are associated with longevity^[22] and Mg enhances probiotic efficacy^[23]. Butyrate produced by gut bacteria via vagal afferents may improve HRV^{[24][25]}. Candida and cancer cells are prominent secretagogues for HDAC^{[26][27]}. Butyrate is an HDACi^[28] and may also mediate the efficacy of calorie restriction in enhancing longevity^[29]. Gut microbiota cannot produce SCFAs in the absence of Mg^[30]. Omega-3 fish oils upregulate SCFA production, especially butyrate^[31] and enhance biodiversity^[32].

II. Vitamin D

Vitamin D is another well-recognized longevity agent^[33] and Mg is critical to its synthesis^[34]. The active forms of vitamin B2 (FAD) and B3 (NAD), required for

the synthesis of the D3 precursor, 7-dehydrocholesterol, are also Mg dependent (see figure 2).




Figure 2. This sterol biosynthetic pathway for cholecalciferol decreases with age and is further challenged by Mg deficiency. The intensity of red arrows indicates the impact of Mg deficiency. DHC=dehydrocholesterol, PTH=parathormone, VDBP=vitamin D binding protein, D3=cholecalciferol

Vitamin D efficacy in longevity is linked to its healthful effects on methylation and the epigenome^[35]. Vitamin D supplementation reduces total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels but not HDL-C levels^[36] (see section V). Vitamin D reversibly improves the gut microbiome^[37]. D3 directly inhibits *Candida* hyphal morphogenesis. *Candida* can produce its own IDO, which depletes tryptophan, upregulates the kynurenine pathway, and alters tryptophan metabolism (ATM)^[38].

III. Telomeres

The link between telomere length and mortality, like HDL-C (section V), may be U-shaped. Initially, telomere length was reported as positively linked to longevity. However, recently, this has been challenged. Long telomeres may be associated with cancers^[39]. Telomeres shorten with age (attrition), and longevity is characterized by less telomere attrition, i.e., longer telomeres versus those less long-lived^[40]. This shortening is due to the loss of telomere homeostasis with cellular senescence. Mg maintains telomere homeostasis^[41]. Anti-aging agents and conditions that delay telomere shortening include vitamin D^[42], dietary Mg^[43], calorie restriction^[44], and GLP-1^[45]. Telomere attrition is influenced by oxidative stress, inflammation, insulin resistance, and hyperglycemia, well controlled by GLP-1^[46]. Gilbert's Syndrome also manifests less telomere attrition^[47]. Regulation of telomerase and telomere homeostasis is subject to epigenetic control and DNA methylation^[48] (see section VIII).

IV. AhR

Recently, the vital role of aryl hydrocarbon receptors (AhRs) in aging^[49], dementia, autoimmune disease, cancer^[50], and ASCVD^[51] has been recognized. AhR activity is dependent on its ligands. Kynurenines are AhR ligands that accelerate aging and neurodegeneration, while butyrates and indoles of intestinal bacterial origin are AhR ligands that oppose this^[49] and promote longevity. ATM inactivates the immune response-dependent function of AhR^[52]. Not only are indoles and butyrate AhR ligands^[53], but subsequent AhR activation induces cytochrome CYP450 enzymes that facilitate the gut absorption of indoles^[54]. All CYP450 enzymes are Mg dependent^[11]. Indole derivatives also stimulate butyrate-producing gram-positive bacteria^[54].

V. HDL-C

HDL-C has long been linked to longevity^[55]. However, more recent studies report that the HDL-CVD relationship is U-shaped, i.e., low and extremely high HDL-C levels can entail health risks^[56]. Mechanisms underlying this non-linear relationship are presently unknown. However, one study suggests that the capacity of HDL to acquire free cholesterol during triglyceride-rich lipoprotein (TGRL) lipolysis by lipoprotein lipase underlies the non-linear relationship between HDL-C and cardiovascular risk^[57]. Lipoprotein lipase (LPL)-induced lipolysis removes blood triglycerides. Elevated triglycerides directly compromise the ability of HDL to clear cholesterol, as HDL-C increases above 100 mg/dL. This creates a scenario of elevated but ineffectual HDL-C in a triglyceride-rich environment, hypothetically explaining the increase in CVD despite extremely high HDL-C. LPL-mediated lipolysis is the rate-limiting step in the removal of triglycerides from the bloodstream^[58] and also regulates HDL-C. LPL is Mg dependent^[59]. Perhaps a Mg shortfall and its consequent impact on rate-limiting LPL contribute to the increase in CVD, despite high HDL-C. Might Mg deficiency compromise the efficacy of elevated HDL-C just as it compromises the efficacy of vitamin D3 (see figure 2)?

VI. HRV

Serum HDL-C levels correlate with high-frequency HRV indices^[60]. Low total cholesterol and LDL-C were significantly associated with low-frequency HRV indices^[61]. Not surprisingly, HRV is another well-recognized longevity agent^[62].

It can predict disease well before symptoms appear^[63] and directly reflects vagal tone^[64]. The anti-aging butyrate suppresses food intake via vagal signals to the brain^[65].

Calorie restriction also improves HRV^[66]. The impact of HRV and calorie restriction on longevity suggests that the appetite-suppressing properties of butyrogenic gut bacteria via vagal afferents may increase HRV. This has recently been reported^[67]. Mg level is positively related to HRV, while the Ca/Mg ratio is negatively related to HRV^[68]. Vitamins D and B-12 deficiencies are associated with reduced HRV^[69]. The active forms of both are Mg dependent.

VII. Melatonin, Resveratrol, Vitamin C, Tryptophan, Calorie Restriction, α -Ketoglutarate, Methionine Restriction, and Lactate Dehydrogenase

Two popular decades-old anti-aging supplements are melatonin and resveratrol. Melatonin can be sourced endogenously from the pineal gland or exogenously. Its synthesis from tryptophan is Mg dependent (see figure 1). Melatonin opposes CVD and neurodegenerative disease with antioxidant and anti-inflammatory properties^[70].

Many of the healthful benefits of resveratrol are mediated by Mg-dependent enzymes, e.g., protein and nucleotide kinases. This enables resveratrol to function as anti-cancer, antioxidant, anti-obesity, anti-dementia, anti-T2DM, and anti-CVD^[71]. Moreover, resveratrol and quercetin, proven to extend lifespan, are compounds that can also serve as AhR ligands^[72].

Mg enhances the anti-cancer property of Vitamin C via SCVT (sodium-coupled vitamin C transporter)^{[73][74]}. Tryptophan has recently emerged as a longevity agent^[75]. It opposes the hyphal morphogenesis of *Candida*^[76], associated with decreased healthspan^[77]. ATM is characterized by tryptophan depletion and an increased K/T ratio and is associated with cancer, dementia, autoimmune disease, and T2DM^[78].

Alpha-ketoglutarate is another recently discovered longevity agent, prominent in the Krebs cycle. Its longevity property mimics calorie restriction via dietary restriction and inhibition of ATP synthase^[79]. However, Mg enhances the efficacy of calorie restriction^[80] and probably α -KG as well. Both depress oxidative stress. In addition, the enzymes responsible for the synthesis of α -KG and glutamine from glutamate are both Mg-dependent. Any Mg deficiency may increase glutamate, an anti-aging and dementia-promoting agent^[81].

Methionine restriction (MR) also possesses longevity properties via a mechanism similar to that of calorie restriction^[82]. These include anti-cancer, anti-aging, anti-inflammatory, and anti-obesity^[83]. The benefits of MR may be due to reduced oxidative stress and redox status changes through mechanisms not yet discovered^[82]. Six of ten enzymes in the Krebs Cycle are dehydrogenases (Mg-dependent). These are mitochondrial electron transfer reactions (redox reactions) that also require magnesium-dependent B2 as flavin adenine dinucleotide (FAD) and B3 as niacinamide adenine dinucleotide (NAD). MR longevity benefits may be due to a reduction in free radical leakage from mitochondria^[82]. B2 and B3 protect mitochondria from oxidative stress, e.g., transsulfuration pathway and glutathione synthesis^[84] (see figure 3). Consequently, any Mg shortfall may curtail the longevity benefits of MR. It will curtail the production of glutathione, the most powerful human antioxidant (see figure 3).

Not surprisingly, another Mg-dependent dehydrogenase, lactate dehydrogenase (LDH), is a longevity biomarker, albeit an inverse one^[85]. It converts lactic acid to pyruvate, its most critical function^[86]. While blood lactate is bad, gut lactate is good. During exercise, blood lactate can enter the gut and feed butyrogenic bacteria^[87].

Lactogenic bacteria, e.g., *Bifidobacteria* and *Lactobacilli*, can also cross-feed butyrogenic bacteria, e.g., *Faecalibacterium* and *Roseburia*^[88] and lower host lactate levels^[89]. Elevated levels of lactate and LDH are linked to cancer (Warburg

a longevity agent itself, both with respect to biochemistry and to the gut microbiome. Seven of nine enzymes in the glycolytic pathway are Mg dependent. In the Krebs cycle, seven of 10 enzymes are Mg dependent. Thus, Mg deficiency negatively impacts ATP production and increases oxidative stress. Mg deficiency is linked to insulin resistance, an early hallmark of cancer, T2DM, and T3DM. Mg is critical to the kynurenine pathway (see figure 1) and the production of NAD⁺. ATM characterizes cancer, dementia, autoimmune disease, and T2DM^[78]. Mg-dependent phosphoribosyl transferases and adenylyl transferases, key enzymes determining aging^[98], convert quinolinic acid (neurotoxic) to NAD⁺ and nicotinamide adenine mononucleotide (NAM) to NAD⁺ respectively (see figure 1). NAD⁺ decreases with age^[99], while Mg deficiency increases with age^[4]. Thus, Mg deficiency compromises the ability to recycle NAD⁺, enhancing risks due to stress, inflammaging, disease, and dysbiosis.

ATM is linked to gut dysbiosis^[100], which is linked to the gut microbiome^[101]. Mg status is also directly linked to gut microbiota. A Mg-deficient diet reduces the abundance of Bifidobacterium. A Mg-rich diet increases both biodiversity and the abundance of Bifidobacterium^[102]. The Mediterranean diet, rich in Mg, enhances biodiversity and the growth of lactobacilli and bifidobacteria^[103]. Lactobacillus spp. can significantly increase the bioavailability of magnesium^[102]. These lactogenic bacteria (lactobacilli and bifidobacteria) then crossfeed butyrogenic bacteria, increasing butyrate, an emerging longevity agent (see section IC). The gut microbiome of centenarians exhibits increased activity in the phosphatidyl-inositol pathway and glycosphingolipid biosynthesis^[104]. The phosphatidyl-inositol pathway starts with the magnesium-dependent conversion of glucose to glucose-6-phosphate. Subsequent pathway steps are also heavily dependent on ATP and cAMP, both of which are Mg dependent. Glycosphingolipid biosynthesis involves glycosyltransferases and glucosidases. Most glycosyltransferases are Mg dependent, and some β -glucosidases are enhanced by Mg⁺⁺^[105]. The gut microbiome of the younger elderly shows decreased saccharolytic capacity (aka glucose metabolism) and low levels of SCFAs, tryptophan, indole, and nicotinamide^[104]. All of these are longevity agents and have been discussed in depth. Yet awareness of Mg deficiency has always been subordinate to that of Ca, e.g., routine chemistry panels offer Ca but not Mg. Few realize that they are antagonists. Ca:Mg is rarely mentioned.

A. Ca:Mg

The calcium-sensing receptor (CaSR) is a Mg-dependent G protein-coupled receptor activated by Ca⁺⁺ or Mg⁺⁺^{[106][107]}. Most of the focus on Mg and vitamin D pertains to the criticality of Mg in the synthesis of the sunshine vitamin. But vitamin D improves the absorption of not only Ca but also Mg, although to a lesser extent^[108]. The active forms of Ca and Mg are their cations (Ca⁺⁺, Mg⁺⁺). Both bind to the CaSR, and excess Ca⁺⁺ can competitively inhibit Mg⁺⁺. In the Western diet, Ca outweighs Mg. According to NHANES (National Health and Nutrition Examination Surveys), the mean dietary intake of Ca:Mg for Americans has escalated from 2.6 in 1977 to over 3.0 since 2000. Between 1977 and 2012, US Ca intake increased at a rate 2 - 2.5 times that of Mg^[109]. In 1989, Jean Durlach, founder of the International Society for Development of Research on Magnesium, reported that 2.0 was the proper target ratio (circulating cation concentrations in mM). An elevated Ca:Mg ratio is characteristic of cancer,

autoimmune disease^[110] and ASCVD^[111] and this ratio should be maintained between 1.7 and 2.8^[109]. The Oriental diet is typically low in Ca, while the Occidental diet is typically low in Mg^[112]. This Ca:Mg imbalance is often overlooked because a) Mg is not usually included in any lab chemistry panel, b) the lower limit on the “normal” range may be too low, and c) serum Mg (bound and free) does not reflect Mg⁺⁺. The median intake of Mg is insufficient to fully exploit the healthful benefits of vitamin D, especially for CVD and colon cancer^[113]. This suggests that the lower limit of “normal” lab serum Mg⁺⁺ values (.75-.95 mM), determined by extensive sampling from this large “healthy” population (50% are deficient), is too low. Several studies have suggested .85 mM as a lower limit^{[114][115]}. Yet lab range values for serum Mg⁺⁺ in healthy controls remain unchanged, despite repeated alerts over the past two dozen years^{[116][117][118]}. Another study of 91 participants found that a detailed diet questionnaire predicted suboptimal Mg status in 100%, yet lab testing confirmed this in only 76%^[119]. Might this also challenge the validity of .75 mM as a lower limit? This gray zone between .75 and .85 may correspond to low intra-erythrocytic Mg when serum Mg is within normal limits. Initially termed normomagnesemia Mg deficiency^[5], it is now known as chronic latent Mg deficit. This has been demonstrated for migraines and PMS^[5].

Calculation of serum Mg⁺⁺ in “healthy” individuals with normal renal function, with midrange serum albumin, and without medications can most likely be determined from serum Mg (bound and unbound). If one compares the normal ranges for serum Mg and Ca with the normal ranges for ionized Mg and Ca, they align exactly, but only if Mg⁺⁺ and Ca⁺⁺ represent 70% and 50% of total serum levels, respectively. When the midpoints of the ranges for the ionized forms (Ca⁺⁺ = 1.2 mM, Mg⁺⁺ = .6 mM) are determined, the Ca:Mg ratio is 2.0, very much in line with Durlach’s recommendation.

This means that if the lower limit of normal for serum Mg were to be raised to .85 mM (2.0 mg/dL), then to maintain this recommended ratio, the lower limit of normal for serum Ca should be raised to ~2.4 mM (9.5 mg/dL). This increase in the lower limit of normal Ca, in addition to Mg, seems appropriate. According to the NIH, data from NHANES 2009–2010 indicated that 42% of Americans did not meet their Estimated Average Requirements for Ca as recommended by the Institute of Medicine^[120]. The prevalence of Ca deficiency is even greater in low- and middle-income countries^[121].

B. Magnesium and Covid-19

Ca:Mg > 5.0 is strongly associated with Covid-19 mortality^[122]. Mg levels directly correlate with Covid-19 disease for risk of hospitalization, length of stay, mortality, and long Covid^[123]. Ca:Mg might even further refine this link with severity. Among individuals less than 65 years old with Ca:Mg > 2.6, reducing the ratio to around 2.3 downregulated the TMPRSS2 gene. Decreasing Ca:Mg improved methylation and ameliorated or prevented Covid-19^[124]. Aberrant methylation is not only a biomarker for Covid-19 but also for long Covid^[125]. This suggests that those with the 677T MTHFR variant allele (half of Americans) are at greater risk, as has been reported^[126].

ACE2 receptor-bearing cells are targeted and lysed by SARS CoV2. Intestinal epithelial cells are rich in ACE2 receptors. This is problematic because these

receptors must complex with B⁰ATs (neutral or nonpolar amino acid transporters) to enable absorption of tryptophan. Tryptophan, a longevity agent, opposes Candida hyphal morphogenesis^[76]. Candida produces its own IDO^[76] that competes with host IDO and drives ATM^[38] (see figure 1).

In summary, the dozen or so longevity agents evaluated in this review appear to be linked to Mg, either directly in the synthesis of the agent or indirectly along the relevant metabolic pathway. Although the magnitude of their impact in any individual is complex and impossible to quantitate, their limited presence in those on a Western diet or lifestyle is difficult to deny. Additional longevity agents may yet be discovered, expanding options in our quest for longevity. Figure 4 illustrates their interlinkage.




Figure 4. All blue boxes are directly associated with longevity. Green boxes are Mg++ dependent. Red boxes are anti-longevity. Green arrows promote, and red arrows inhibit. PUFAs=polyunsaturated fatty acids, HDAC=histone deacetylase, GLP=glucagon like peptide, CYP=cytochrome P, AhR=aryl hydrocarbon receptor, HRV=heart rate variability, HDL-C= high density lipoprotein cholesterol, LP=lipoprotein

C. Therapeutic Interventions

The first step in addressing a potential Mg shortage is to assess Ca:Mg. If greater than 2.6, then efforts must be directed to lowering the oral intake of Ca. Otherwise, increasing oral Mg will lower PTH and suppress Mg absorption. Administering a variety of Mg chelates, e.g., glycinate, maleate, taurate, threonate, also enhances absorption. Bowel tolerance should be the limiting factor and should be approached slowly. Mg citrate is especially noted for its laxative side effect. Combining the oral intake of Mg with vitamin D is also helpful.

Mg bioavailability is increased by the concomitant intake of the active form of vitamin B, pyridoxal phosphate (PLP)^[127]. PLP, but not pyridoxine, appears to form a complex with Mg and hence may enhance the transport or accumulation of Mg in cells^[128]. However, several old and recent articles have challenged this beneficial effect of B6 on Mg absorption^{[129][130]}, but both employed Magne, which is 300 mg Mg and 30 mg pyridoxine. Another article claimed that B6 enhances erythrocytic Mg but only at high doses and that high doses risk peripheral neuropathy. This study also used Magne^[131].

Even the NIH, in its Aug 2023 update on B6, failed to acknowledge the efficacy differential between pyridoxine and PLP. Furthermore, taking P5P concomitantly with Mg can potentially double^[127] or triple^[128] the absorption of Mg. Not only does PLP enhance the cellular uptake of Mg, but Mg also enhances that of PLP^[132]. B6 as pyridoxine, the inactive form and the most common form in B supplements, competitively inhibits P5P, the active form, and can cause peripheral neuropathy^[133]. B2 as FAD is a Mg-dependent and required cofactor for the synthesis of PLP. This means that if B2 is deficient without PLP supplementation, then B6 supplementation as pyridoxine can cause symptoms of B6 deficiency. The synthesis of PLP is also Mg dependent.

Not surprisingly, B vitamins are linked to longevity^[134]. Of the eight, six require Mg to attain activated status. B1 as thiamine pyrophosphate, B2 as FAD, B3 as NAD, and B6 as pyridoxal phosphate require phosphorylation. B9 and B12 require methylation. All phosphorylation and methylation reactions require Mg. All five of these B vitamins are critical to methylation (see figure 3). The value of a prebiotic, e.g., sauerkraut, kimchi, D-mannose, a probiotic, e.g., yogurt, and a postbiotic, e.g., butyrate, in the quest for a better gut microbiome and healthful longevity cannot be underestimated. Fecal microbiota transplantation has shown significant efficacy in treating cancer^[135], autoimmune disease^[136], and dementia^[137]. This suggests that it is never too late to upgrade your gut microbiome in any therapeutic approach to disease, much less any preventative one (see figure 4).

3. Conclusion

Bile acids and HDL-C are longevity agents that necessitate hepatic metabolism by magnesium-dependent CYP450 enzymes. The production of indoles by gut bacteria also requires magnesium-dependent CYP450 enzymes. The syntheses of the active forms of vitamins D, B1, B2, B3, B6, B9, and B12 are magnesium dependent. These activated B vitamins and Mg⁺⁺ are all required cofactors in the remethylation (folate) and transmethylation (methionine) cycles, critical to the epigenome. Any shortfall in Mg status will weaken methylation and exacerbate the significant health problems associated with the MTHFR 677T variant allele, present in the majority of Americans (see figure 3). Aberrant methylation compromises the immune response to SARS CoV2 and increases the risk for long Covid. Mg actively suppresses obesity and T2DM. The longevity properties of Mg are highly dependent on Ca:Mg, rarely mentioned in contrarian reviews on the benefits of vitamin D or Mg supplementation. Compromised recycling of NAD⁺ due to Mg deficiency (see figure 1) and upregulation of IDO by host IFN-gamma, cancer cells, and Candida drive ATM, linked to cancer, dementia, autoimmune disease, T2DM, oxidative stress, inflammaging, and dysbiosis, are all opposed by a healthy gut microbiome. Health problems related to normomagnesemia Mg deficiency, e.g., migraines and premenstrual syndrome, challenge the validity of

the accepted lower limit for serum Mg. Multiple interlinked biomarkers indicative of healthful aging are Mg dependent. Mg potentiates the healthful benefits of the gut microbiome and vice versa. Unfortunately, Mg status has steadily declined primarily due in part to

1. the deteriorating quality of our food
2. the popularity of refined carbohydrates and alcohol
3. the prevalence of antibiotics and other medications, e.g., proton pump inhibitors
4. the high Ca:Mg in supplements (mean ratio of 2.9 in those containing both)^[138] that is even higher in women
5. the lack of Mg awareness (not offered on routine chemistry panels)
6. the presence of widespread, unrecognized, mild, chronic dehydration (aldosterone wastes magnesium)^{[139][140]}
7. the absence of exercise (reduces aldosterone)^[141]
8. the increasing tendency toward obesity (increases aldosterone)^[142]
9. Stress (cortisol also activates mineralocorticoid receptors)^[143].

Indeed, optimal hydration itself may slow down the aging process^[144] and secondary Mg deficiency may be the primary pathway to premature mortality. Although the discussed biochemistry and physiology are generally accepted, convincing clinical studies, adjusted for D3 and Ca status, supporting the underappreciated role of Mg in longevity, await.

“Every known illness is associated with a magnesium deficiency,”
Norman Shealy, Father of Holistic Medicine

Statements and Declarations

Data Availability

No new data were created or analyzed in this study. Data sharing is not applicable to this article as all information discussed is derived from previously published research cited within the text.

Author Contributions

PC conceived the idea, conducted the literature review, wrote the manuscript, and approved the final version.

Notes

The following references^{[145][146][147][148][149][150][151][152][153][154][155]} appear only in Figure 4.

References

1. [^]Fiorentini D, Cappadone C, Farruggia G, Prata C (2021). "Magnesium: Biochemistry, Nutrition, Detection, and Social Impact of Diseases Linked to Its Deficiency." *Nutrients*. **13**(4):1136. doi:10.3390/nu13041136.
2. [^]Workinger JL, Doyle RP, Bortz J (2018). "Challenges in the Diagnosis of Magnesium Status." *Nutrients*. **10**(9):1202. doi:10.3390/nu10091202.

3. ^a, ^b Dominguez LJ, Veronese N, Barbagallo M (2024). "Magnesium and the Hallmarks of Aging." *Nutrients*. 16(4):496. doi:[10.3390/nu16040496](https://doi.org/10.3390/nu16040496).
4. ^a, ^b Killilea DW, Maier JA (2008). "A connection between magnesium deficiency and aging: new insights from cellular studies." *Magn Res*. 21(2):77–82. <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2790427/>.
5. ^a, ^b, ^c Mansmann HC Jr (1993). "Consider Magnesium Homeostasis: II: Staging of Magnesium Deficiencies." *Pediatric Allergy, Immunology and Pulmonology*. 7:211–215. doi:[10.1089/pai.1993.7.211](https://doi.org/10.1089/pai.1993.7.211).
6. ^a Jin L, Shi L, Huang W (2024). "The role of bile acids in human aging." *Med Rev* (2021). 4(2):154–157. doi:[10.1515/mr-2024-0003](https://doi.org/10.1515/mr-2024-0003).
7. ^a Masse KE, Lu VB (2023). "Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease." *Front Endocrinol (Lausanne)*. 14:1169624. doi:[10.3389/fendo.2023.1169624](https://doi.org/10.3389/fendo.2023.1169624).
8. ^a, ^b Chavda VP, Balar PC, Vaghela DA, Dodiya P (2024). "Unlocking longevity with GLP-1: A key to turn back the clock?." *Maturitas*. 186:108028. doi:[10.1016/j.maturitas.2024.108028](https://doi.org/10.1016/j.maturitas.2024.108028).
9. ^a Peng W, Zhou R, Sun ZF, Long JW, Gong YQ (2022). "Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases." *Aging and disease*. 13(2):468–490. doi:[10.14336/AD.2021.0928](https://doi.org/10.14336/AD.2021.0928).
10. ^a Huang LY, Liu CH, Chen FY, Kuo CH, Pitrone P, Liu JS (2023). "Aging Affects Insulin Resistance, Insulin Secretion, and Glucose Effectiveness in Subjects with Normal Blood Glucose and Body Weight." *Diagnostics (Basel)*. 13(13):2158. doi:[10.3390/diagnostics13132158](https://doi.org/10.3390/diagnostics13132158).
11. ^a, ^b, ^c Mansmann HC Jr (1994). "Consider magnesium homeostasis: III: cytochrome P450 enzymes and drug toxicity." *Applied Immunohistochemistry & Molecular Morphology*. 8:7–28. doi:[10.1089/pai.1994.8.7](https://doi.org/10.1089/pai.1994.8.7).
12. ^a Fuchs CD, Trauner M (2022). "Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology." *Nat Rev Gastroenterol Hepatol*. 19:432–450. doi:[10.1038/s41575-021-00566-7](https://doi.org/10.1038/s41575-021-00566-7).
13. ^a Wise JL, Cummings BP (2023). "The 7- α -dehydroxylation pathway: An integral component of gut bacterial bile acid metabolism and potential therapeutic target." *Front Microbiol*. 13:1093420. doi:[10.3389/fmicb.2022.1093420](https://doi.org/10.3389/fmicb.2022.1093420).
14. ^a Vico-Oton E, Volet C, Jacquemin N, et al. (2024). "Strain-dependent induction of primary bile acid 7-dehydroxylation by cholic acid." *BMC Microbiol*. 24:286. doi:[10.1186/s12866-024-03433-y](https://doi.org/10.1186/s12866-024-03433-y).
15. ^a Ji S, Pan Y, Zhu L, Tan J, Tang S, Yang Q, Zhang Z, Lou D, Wang B (2021). "A novel 7 α -hydroxysteroid dehydrogenase: Magnesium ion significantly enhances its activity and thermostability." *Int J Biol Macromol*. 177:111–118. doi:[10.1016/j.ijbiomac.2021.02.082](https://doi.org/10.1016/j.ijbiomac.2021.02.082).
16. ^a Horsfall LJ, Nazareth I, Pereira SP, Petersen I (2013). "Gilbert's syndrome and the risk of death: a population-based cohort study." *J Gastroenterol Hepatol*. 28(10):1643–7. doi:[10.1111/jgh.12279](https://doi.org/10.1111/jgh.12279).
17. ^a Wagner KH, Khoei NS, Hana CA, Doberer D, Marculescu R, Bulmer AC, Hörmann-Wallner M, Mölzer C (2021). "Oxidative Stress and Related Biomarkers in Gilbert's Syndrome: A Secondary Analysis of Two Case-Control Studies." *Antioxidants (Basel)*. 10(9):1474. doi:[10.3390/antiox10091474](https://doi.org/10.3390/antiox10091474).
18. ^a Matoba N, Une M, Hoshita T (1986). "Identification of unconjugated bile acids in human bile." *J Lipid Res*. 27(11):1154–62. doi:[10.1016/S0022-2275\(20\)38751-4](https://doi.org/10.1016/S0022-2275(20)38751-4).

19. [△]Li XJ, Fang C, Zhao RH, Zou L, Miao H, Zhao YY (2024). "Bile acid metabolism in health and ageing-related diseases." *Biochem Pharmacol.* 225:116313. doi:[10.1016/j.bcp.2024.116313](https://doi.org/10.1016/j.bcp.2024.116313).
20. [△]Oxenkrug G, Navrotska V (2023). "Extension of life span by down-regulation of enzymes catalyzing tryptophan conversion into kynurenine: Possible implications for mechanisms of aging." *Exp Biol Med (Maywood)*. 248(7):573–577. doi:[10.1177/15353702231179411](https://doi.org/10.1177/15353702231179411).
21. [△]Gribble FM, Reimann F (2021). "Metabolic Messengers: glucagon-like peptide 1." *Nat Metab.* 3:142–148. doi:[10.1038/s42255-020-00327-x](https://doi.org/10.1038/s42255-020-00327-x).
22. [△]Chaudhary P, Kathuria D, Suri S, Bahndral A, Kanthi Naveen A (2023). "Probiotic s– its functions and influence on the ageing process: A comprehensive review." *Food Bioscience*. doi:[10.1016/j.fbio.2023.102389](https://doi.org/10.1016/j.fbio.2023.102389).
23. [△]Mahboobi S, Ghasvarian M, Ghaem H, Alipour H, Alipour S, Eftekhari MH (2022). "Effects of probiotic and magnesium co-supplementation on mood, cognition, intestinal barrier function and inflammation in individuals with obesity and depressed mood: A randomized, double-blind placebo-controlled clinical trial." *Front Nutr.* 9:1018357. doi:[10.3389/fnut.2022.1018357](https://doi.org/10.3389/fnut.2022.1018357).
24. [△]Seefeldt JM, Homilius C, Hansen J, Lassen TR, Jespersen NR, Jensen RV, et al. (2024). "Short-Chain Fatty Acid Butyrate Is an Inotropic Agent With Vasorelaxant and Cardioprotective Properties." *Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease*. 13. doi:[10.1161/JAHA.123.033744](https://doi.org/10.1161/JAHA.123.033744).
25. [△]Yu Z, Han J, Chen H, Wang Y, Zhou L, Wang M, et al. (2021). "Oral Supplementation With Butyrate Improves Myocardial Ischemia/Reperfusion Injury via a Gut-Brain Neural Circuit." *Front Cardiovasc Med.* 8:718674. doi:[10.3389/fcvm.2021.718674](https://doi.org/10.3389/fcvm.2021.718674).
26. [△]Su S, Li X, Yang X, Li Y, Chen X, Sun S, Jia S (2020). "Histone acetylation/deacetylation in *Candida albicans* and their potential as antifungal targets." *Future Microbiol.* 15:1075–1090. doi:[10.2217/fmb-2019-0343](https://doi.org/10.2217/fmb-2019-0343).
27. [△]Alseksek RK, Ramadan WS, Saleh E, El-Awady R (2022). "The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention." *Int J Mol Sci.* 23(15):8141. doi:[10.3390/ijms23158141](https://doi.org/10.3390/ijms23158141).
28. [△]Yu R, Cao X, Sun L, et al. (2021). "Inactivating histone deacetylase HDA promotes longevity by mobilizing trehalose metabolism." *Nat Commun.* 12:1981. doi:[10.1038/s41467-021-22257-2](https://doi.org/10.1038/s41467-021-22257-2).
29. [△]Silva YP, Bernardi A, Frozza RL (2020). "The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication." *Front Endocrinol (Lausanne)*. 11:25. doi:[10.3389/fendo.2020.00025](https://doi.org/10.3389/fendo.2020.00025).
30. [△]Sasaki H, Hayashi K, Imamura M, Hirota Y, Hosoki H, Nitta L, et al. (2023). "Combined resistant dextrin and low-dose Mg oxide administration increases short-chain fatty acid and lactic acid production by gut microbiota." *J Nutr Biochem.* 120:109420. doi:[10.1016/j.jnutbio.2023.109420](https://doi.org/10.1016/j.jnutbio.2023.109420).
31. [△]Nogal A, Valdes AM, Menni C (2021). "The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health." *Gut Microbes.* 13(1):1–24. doi:[10.1080/19490976.2021.1897212](https://doi.org/10.1080/19490976.2021.1897212).
32. [△]Menni C, Zierer J, Pallister T, Jackson MA, Long T, Mohnsey RP, Steves CJ, Spector TD, Valdes AM (2017). "Omega-3 fatty acids correlate with gut microbiome diversity and production of N-carbamylglutamate in middle aged and elderly women." *Scientific Reports.* 7:11079. doi:[10.1038/s41598-017-10382-2](https://doi.org/10.1038/s41598-017-10382-2).
33. [△]Fantini C, Corinaldesi C, Lenzi A, Migliaccio S, Crescioli C (2023). "Vitamin D as a Shield against Aging." *International Journal of Molecular Sciences.* 24(5):4546. doi:[10.3390/ijms24054546](https://doi.org/10.3390/ijms24054546).

34. [△]Rude RK, Adams JS, Ryzen E, Endres DB, Niimi H, Horst RL, Haddad JG Jr, Singer FR (1985). "Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency." *The Journal of Clinical Endocrinology & Metabolism*. **61**(5):933–40. doi:[10.1210/jcem-61-5-933](https://doi.org/10.1210/jcem-61-5-933).
35. [△]Ong LTC, Booth DR, Parnell GP (2020). "Vitamin D and its Effects on DNA Methylation in Development, Aging, and Disease." *Molecular Nutrition & Food Research*. **64**(23):e2000437. doi:[10.1002/mnfr.202000437](https://doi.org/10.1002/mnfr.202000437).
36. [△]Dibaba DT (2019). "Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis." *Nutrition Reviews*. **77**(12):890–902. doi:[10.1093/nutrit/nuz037](https://doi.org/10.1093/nutrit/nuz037).
37. [△]Thomas RL, Jiang L, Adams JS, Xu ZZ, Shen J, Janssen S, Ackermann G, Vanderschueren D, Pauwels S, Knight R, Orwoll ES, Kado DM (2020). "Vitamin D metabolites and the gut microbiome in older men." *Nature Communications*. **11**:5997. doi:[10.1038/s41467-020-19793-8](https://doi.org/10.1038/s41467-020-19793-8).
38. [△]^a Kherad Z, Yazdanpanah S, Saadat F, Pakshir K, Zomorodian K (2023). "Vitamin D3: A promising antifungal and antibiofilm agent against *Candida* species." *Curr Med Mycol*. **9**(2):17–22. PMID [38375518](https://pubmed.ncbi.nlm.nih.gov/38375518/).
39. [△]DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, Gable DL, Xiang Z, Lombard DB, Antonarakis ES, Gocke CD, McCoy RC, Armanios M (2023). "Familial Clonal Hematopoiesis in a Long Telomere Syndrome." *New England Journal of Medicine*. **388**(26):2422–2433. doi:[10.1056/NEJMoa2300503](https://doi.org/10.1056/NEJMoa2300503).
40. [△]Ye Q, Apsley AT, Etzel L, Hastings WJ, Kozlosky JT, Walker C, Wolf SE, Shalev I (2023). "Telomere length and chronological age across the human lifespan: A systematic review and meta-analysis of 414 study samples including 743,019 individuals." *Ageing Research Reviews*. **90**:102031. doi:[10.1016/j.arr.2023.102031](https://doi.org/10.1016/j.arr.2023.102031).
41. [△]Maguire D, Neytchev O, Talwar D, McMillan D, Shiels PG (2018). "Telomere Homeostasis: Interplay with Magnesium." *International Journal of Molecular Sciences*. **19**(1):157. doi:[10.3390/ijms19010157](https://doi.org/10.3390/ijms19010157).
42. [△]Richards JB, Valdes AM, Gardner JP, Paximadas D, Kimura M, Nessa A, Lu X, Surdulescu GL, Swaminathan R, Spector TD, Aviv A (2007). "Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women." *The American Journal of Clinical Nutrition*. **86**(5):1420–5. doi:[10.1093/ajcn/86.5.1420](https://doi.org/10.1093/ajcn/86.5.1420).
43. [△]Hu L, Bai Y, Hu G, Zhang Y, Han X, Li J (2022). "Association of Dietary Magnesium Intake With Leukocyte Telomere Length in United States Middle-Aged and Elderly Adults." *Frontiers in Nutrition*. **9**:840804. doi:[10.3389/fnut.2022.840804](https://doi.org/10.3389/fnut.2022.840804).
44. [△]Hastings WJ, Ye Q, Wolf SE, Ryan CP, Das SK, Huffman KM, Kobor MS, Kraus WE, MacIsaac JL, Martin CK, Racette SB, Redman LM, Belsky DW, Shalev I (2024). "Effect of long-term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis." *Aging Cell*. **23**(6):e14149. doi:[10.1111/acer.14149](https://doi.org/10.1111/acer.14149).
45. [△]Ridout KK, Syed SA, Kao HT, Porton B, Rozenboym AV, Tang J, Fulton S, Perera T, Jackowski AP, Kral JG, Tyrka AR, Coplan J (2021). "Relationships Between Telomere Length, Plasma Glucagon-like Peptide 1, and Insulin in Early-Life Stress-Exposed Nonhuman Primates." *Biological Psychiatry Global Open Science*. **2**(1):54–60. doi:[10.1016/j.bpsgos.2021.07.006](https://doi.org/10.1016/j.bpsgos.2021.07.006).
46. [△]Wang J, Dong X, Cao L, Sun Y, Qiu Y, Zhang Y, Cao R, Covasa M, Zhong L (2016). "Association between telomere length and diabetes mellitus: A meta-analysis." *Journal of International Medical Research*. **44**(6):1156–1173. doi:[10.1177/0300060516667132](https://doi.org/10.1177/0300060516667132).
47. [△]Tosevska A, Moelzer C, Wallner M, Janosec M, Schwarz U, Kern C, Marculescu R, Doberer D, Weckwerth W, Wagner KH (2016). "Longer telomeres in chronic, moder

- ate, unconjugated hyperbilirubinaemia: insights from a human study on Gilbert's Syndrome." *Scientific Reports*. 6:22300. doi:[10.1038/srep22300](https://doi.org/10.1038/srep22300).
48. ^ΔDogan F, Forsyth NR (2021). "Telomerase Regulation: A Role for Epigenetics." *Cancers*. 13(6):1213. doi:[10.3390/cancers13061213](https://doi.org/10.3390/cancers13061213).
 49. ^ΔOjo ES, Tischkau SA (2021). "The Role of AhR in the Hallmarks of Brain Aging: Friend and Foe." *Cells*. 10(10):2729. doi:[10.3390/cells10102729](https://doi.org/10.3390/cells10102729).
 50. ^ΔWang Z, Snyder M, Kenison JE, Yang K, Lara B, Lydell E, Bennani K, Novikov O, F ederico A, Monti S, Sherr DH (2020). "How the AhR Became Important in Cancer: The Role of Chronically Active AhR in Cancer Aggression." *International Journal of Molecular Sciences*. 22(1):387. doi:[10.3390/ijms22010387](https://doi.org/10.3390/ijms22010387).
 51. ^ΔZhu K, Meng Q, Zhang Z, Yi T, He Y, Zheng J, Lei W (2019). "Aryl hydrocarbon receptor pathway: Role, regulation and intervention in atherosclerosis therapy (Review)." *Molecular Medicine Reports*. 20(6):4763–4773. doi:[10.3892/mmr.2019.10748](https://doi.org/10.3892/mmr.2019.10748).
 52. ^ΔSeo SK, Kwon B (2023). "Immune regulation through tryptophan metabolism." *Experimental & Molecular Medicine*. 55(7):1371–1379. doi:[10.1038/s12276-023-01028-7](https://doi.org/10.1038/s12276-023-01028-7).
 53. ^ΔMarinelli L, Martin-Gallausiaux C, Bourhis JM, Bégue-Crespel F, Blottière HM, L apaque N (2019). "Identification of the novel role of butyrate as AhR ligand in human intestinal epithelial cells." *Scientific Reports*. 9:643. doi:[10.1038/s41598-018-37019-2](https://doi.org/10.1038/s41598-018-37019-2).
 54. ^ΔLi X, Zhang B, Hu Y, Zhao Y (2021). "New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases." *Frontiers in Pharmacology*. 12:769501. doi:[10.3389/fphar.2021.769501](https://doi.org/10.3389/fphar.2021.769501).
 55. ^ΔRahilly-Tierney C, Sesso HD, Gaziano JM, Djoussé L (2012). "High-density lipoprotein and mortality before age 90 in male physicians." *Circulation: Cardiovascular Quality and Outcomes*. 5(3):381–6. doi:[10.1161/CIRCOUTCOMES.111.963850](https://doi.org/10.1161/CIRCOUTCOMES.111.963850).
 56. ^ΔFranczyk B, Rysz J, Ławiński J, Rysz-Górczyńska M, Gluba-Brzózka A (2021). "Is a High HDL-Cholesterol Level Always Beneficial?" *Biomedicines*. 9(9):1083. doi:[10.3390/biomedicines9091083](https://doi.org/10.3390/biomedicines9091083).
 57. ^ΔFeng M, Darabi M, Tubeuf E, Canicio A, Lhomme M, Frisdal E, Lanfranchi-Lebreton S, Matheron L, Rached F, Ponnaiah M, Serrano CV Jr, Santos RD, Brites F, Bolbach G, Gautier E, Huby T, Carrie A, Bruckert E, Guerin M, Couvert P, Giral P, Lesnik P, Le Goff W, Guillas I, Kontush A (2020). "Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease." *European Journal of Preventive Cardiology*. 27(15):1606–1616. doi:[10.1177/2047487319894114](https://doi.org/10.1177/2047487319894114).
 58. ^ΔBasu D, Goldberg IJ (2020). "Regulation of lipoprotein lipase-mediated lipolysis of triglycerides." *Current Opinion in Lipidology*. 31(3):154–160. doi:[10.1097/MOL.0000000000000676](https://doi.org/10.1097/MOL.0000000000000676).
 59. ^ΔMathew AA, Panonnummal R (2021). "Magnesium²⁺-the master cation-as a drug-possibilities and evidences." *BioMetals*. 34(5):955–986. doi:[10.1007/s10534-021-00328-7](https://doi.org/10.1007/s10534-021-00328-7).
 60. ^ΔBalikai FA, Javali SB, Shindhe VM, Deshpande N, Benni JM, Shetty DP, Kapoor N, Jaalam K (2022). "Correlation of serum HDL level with HRV indices using multiple linear regression analysis in patients with type 2 diabetes mellitus." *Diabetes Research and Clinical Practice*. 190:109988. doi:[10.1016/j.diabres.2022.109988](https://doi.org/10.1016/j.diabres.2022.109988).
 61. ^ΔLin S, Lee IH, Tsai HC, Chi MH, Chang WH, Chen PS, Chen K, Yang Y (2019). "The association between plasma cholesterol and the effect of tryptophan depletion on heart rate variability." *The Kaohsiung Journal of Medical Sciences*. 35:440–445. doi:[10.1002/kjm2.12067](https://doi.org/10.1002/kjm2.12067).

62. [△]Hernández-Vicente A, Hernando D, Santos-Lozano A, Rodríguez-Romo G, Vicente-Rodríguez G, Pueyo E, et al. (2020). "Heart Rate Variability and Exceptional Longevity." *Frontiers in Physiology*. **11**:566399. doi:[10.3389/fphys.2020.566399](https://doi.org/10.3389/fphys.2020.566399).
63. [△]Jarczok MN, Weimer K, Braun C, Williams DP, Thayer JF, Gündel HO, Balint EM (2022). "Heart rate variability in the prediction of mortality: A systematic review and meta-analysis of healthy and patient populations." *Neuroscience & Biobehavioral Reviews*. **143**:104907. doi:[10.1016/j.neubiorev.2022.104907](https://doi.org/10.1016/j.neubiorev.2022.104907).
64. [△]Gidron Y, Deschepper R, De Couck M, Thayer JF, Velkeniers B (2018). "The Vagus Nerve Can Predict and Possibly Modulate Non-Communicable Chronic Diseases: Introducing a Neuroimmunological Paradigm to Public Health." *Journal of Clinical Medicine*. **7**(10):371. doi:[10.3390/jcm7100371](https://doi.org/10.3390/jcm7100371).
65. [△]Goswami C, Iwasaki Y, Yada T (2018). "Short-chain fatty acids suppress food intake by activating vagal afferent neurons." *The Journal of Nutritional Biochemistry*. **57**:130–135. doi:[10.1016/j.jnutbio.2018.03.009](https://doi.org/10.1016/j.jnutbio.2018.03.009).
66. [△]Nicoll R, Henein MY (2018). "Caloric Restriction and Its Effect on Blood Pressure, Heart Rate Variability and Arterial Stiffness and Dilatation: A Review of the Evidence." *International Journal of Molecular Sciences*. **19**(3):751. doi:[10.3390/ijms19030751](https://doi.org/10.3390/ijms19030751).
67. [△]Tsubokawa M, Nishimura M, Mikami T, Ishida M, Hisada T, Tamada Y (2022). "Association of Gut Microbial Genera with Heart Rate Variability in the General Japanese Population: The Iwaki Cross-Sectional Research Study." *Metabolites*. **12**(8):730. doi:[10.3390/metabo12080730](https://doi.org/10.3390/metabo12080730).
68. [△]Kim YH, Jung KI, Song CH (2012). "Effects of serum calcium and magnesium on heart rate variability in adult women." *Biological Trace Element Research*. **150**(1–3):116–122. doi:[10.1007/s12011-012-9518-2](https://doi.org/10.1007/s12011-012-9518-2).
69. [△]Lopresti AL (2020). "Association between Micronutrients and Heart Rate Variability: A Review of Human Studies." *Advances in Nutrition*. **11**(3):559–575. doi:[10.1093/advances/nmz136](https://doi.org/10.1093/advances/nmz136).
70. [△]Martín Giménez VM, de Las Heras N, Lahera V, Tresguerres JAF, Reiter RJ, Manucha W (2022). "Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases." *Frontiers in Aging Neuroscience*. **14**:888292. doi:[10.3389/fnagi.2022.888292](https://doi.org/10.3389/fnagi.2022.888292).
71. [△]Meng X, Zhou J, Zhao CN, Gan RY, Li HB (2020). "Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review." *Foods*. **9**(3):340. doi:[10.3390/foods9030340](https://doi.org/10.3390/foods9030340).
72. [△]Abudahab S, Price ET, Dozmorov MG, Deshpande LS, McClay JL (2023). "The Aryl Hydrocarbon Receptor, Epigenetics and the Aging Process." *The Journal of Nutrition, Health and Aging*. **27**(4):291–300. doi:[10.1007/s12603-023-1908-1](https://doi.org/10.1007/s12603-023-1908-1).
73. [△]Roa FJ, Peña E, Gatica M, Escobar-Acuña K, Saavedra P, Maldonado M, et al. (2020). "Therapeutic Use of Vitamin C in Cancer: Physiological Considerations." *Frontiers in Pharmacology*. **11**:211. doi:[10.3389/fphar.2020.00211](https://doi.org/10.3389/fphar.2020.00211).
74. [△]Cho S, Chae JS, Shin H, Shin Y, Kim Y, Kil EJ, et al. (2020). "Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation." *Translational Oncology*. **13**(2):401–409. doi:[10.1016/j.tranon.2019.10.017](https://doi.org/10.1016/j.tranon.2019.10.017).
75. [△]Dang H, Castro-Portuguez R, Espejo L, et al. (2023). "On the benefits of the tryptophan metabolite 3-hydroxyanthranilic acid in *Caenorhabditis elegans* and mouse aging." *Nature Communications*. **14**:8338. doi:[10.1038/s41467-023-43527-1](https://doi.org/10.1038/s41467-023-43527-1).
76. [△]^b Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Bellocchio S, et al. (2005). "A Crucial Role for Tryptophan Catabolism at the Host/*Candida albicans*

- Interface." *The Journal of Immunology*. 174(5):2910–2918. doi:[10.4049/jimmunol.174.5.2910](https://doi.org/10.4049/jimmunol.174.5.2910).
77. [△]Chambers PW (2024). "Hyphae and Healthspan: Hypothesis." ResearchGate. doi:[10.13140/RG.2.2.27386.91848](https://doi.org/10.13140/RG.2.2.27386.91848).
 78. [△]^aXue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, et al. (2023). "Tryptophan metabolism in health and disease." *Cell Metabolism*. 35(8):1304–1326. doi:[10.1016/j.cmet.2023.06.004](https://doi.org/10.1016/j.cmet.2023.06.004).
 79. [△]Naeini SH, Mavaddatiyan L, Kalkhoran ZR, Taherkhani S, Talkhabi M (2023). "Alpha-ketoglutarate as a potent regulator for lifespan and healthspan: Evidences and perspectives." *Experimental Gerontology*. 175:112154. doi:[10.1016/j.exger.2023.112154](https://doi.org/10.1016/j.exger.2023.112154).
 80. [△]Abraham KJ, Chan JN, Salvi JS, Ho B, Hall A, Vidya E, et al. (2016). "Intersection of calorie restriction and magnesium in the suppression of genome–destabilizing RNA-DNA hybrids." *Nucleic Acids Research*. 44(18):8870–8884. doi:[10.1093/nar/gkw752](https://doi.org/10.1093/nar/gkw752).
 81. [△]Cox MF, Hascup ER, Bartke A, Hascup KN (2022). "Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer's Disease." *Frontiers in Aging*. 3:929474. doi:[10.3389/fragi.2022.929474](https://doi.org/10.3389/fragi.2022.929474).
 82. [△]^a^b Zhang Y, Jelleschitz J, Grune T, Chen W, Zhao Y, Jia M, et al. (2022). "Methionine restriction – Association with redox homeostasis and implications on aging and diseases." *Redox Biology*. 57:102464. doi:[10.1016/j.redox.2022.102464](https://doi.org/10.1016/j.redox.2022.102464).
 83. [△]Liu Y, Guo J, Cheng H, Wang J, Tan Y, Zhang J, et al. (2024). "Methionine Restriction Diets: Unravelling Biological Mechanisms and Enhancing Brain Health." *Trends in Food Science & Technology*. 149:104532. doi:[10.1016/j.tifs.2024.104532](https://doi.org/10.1016/j.tifs.2024.104532).
 84. [△]Mukherjee S, Banerjee O, Singh S (2023). "The Role of B Vitamins in Protecting Mitochondrial Function." *Molecular Nutrition and Mitochondria*. Chapter 6:167–193. doi:[10.1016/B978-0-323-90256-4.00001-1](https://doi.org/10.1016/B978-0-323-90256-4.00001-1).
 85. [△]Long DM, Frame AK, Reardon PN, Cumming RC, Hendrix DA, Kretschmar D, et al. (2020). "Lactate dehydrogenase expression modulates longevity and neurodegeneration in *Drosophila melanogaster*." *Aging*. 12(11):10041–10058. doi:[10.18632/aging.103373](https://doi.org/10.18632/aging.103373).
 86. [△]Zhou Y, Qi M, Yang M (2022). "Current Status and Future Perspectives of Lactate Dehydrogenase Detection and Medical Implications: A Review." *Biosensors*. 12(12):1145. doi:[10.3390/bios12121145](https://doi.org/10.3390/bios12121145).
 87. [△]Louis P, Duncan SH, Sheridan PO, Walker AW, Flint HJ (2022). "Microbial lactate utilisation and the stability of the gut microbiome." *Gut Microbiome*. 3:e3. doi:[10.1017/gmb.2022.3](https://doi.org/10.1017/gmb.2022.3).
 88. [△]Singh V, Lee G, Son H, Koh H, Kim ES, Unno T, et al. (2023). "Butyrate producers, 'The Sentinel of Gut': Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics." *Frontiers in Microbiology*. 13:1103836. doi:[10.3389/fmicb.2022.1103836](https://doi.org/10.3389/fmicb.2022.1103836).
 89. [△]Lee MC, Hsu YJ, Ho HH, Hsieh SH, Kuo YW, Sung HC, et al. (2020). "Lactobacillus salivarius Subspecies salicinius SA-03 is a New Probiotic Capable of Enhancing Exercise Performance and Decreasing Fatigue." *Microorganisms*. 8(4):545. doi:[10.3390/microorganisms8040545](https://doi.org/10.3390/microorganisms8040545).
 90. [△]Gupta GS (2022). "The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients." *Inflammation*. 45(6):2091–2123. doi:[10.1007/s10753-022-01680-7](https://doi.org/10.1007/s10753-022-01680-7).
 91. [△]Seale K, Horvath S, Teschendorff A, Eynon N, Voisin S (2022). "Making sense of the ageing methylome." *Nat Rev Genet*. 23:585–605. doi:[10.1038/s41576-022-0047](https://doi.org/10.1038/s41576-022-0047)

7-6.

92. ^ΔSalameh Y, Bejaoui Y, El Hajj N (2020). "DNA Methylation Biomarkers in Aging and Age-Related Diseases." *Front Genet.* **11**:171. doi:[10.3389/fgene.2020.00171](https://doi.org/10.3389/fgene.2020.00171).
93. ^ΔHorvath S, Raj K (2018). "DNA methylation-based biomarkers and the epigenetic clock theory of ageing." *Nat Rev Genet.* **19**:371–384. doi:[10.1038/s41576-018-0004-3](https://doi.org/10.1038/s41576-018-0004-3).
94. ^ΔMilicic L, Porter T, Vacher M, Laws SM (2023). "Utility of DNA Methylation as a Biomarker in Aging and Alzheimer's Disease." *J Alzheimers Dis Rep.* **7**(1):475–503. doi:[10.3233/ADR-220109](https://doi.org/10.3233/ADR-220109).
95. ^Δ"MTHFR Gene Variant and Folic Acid Facts." CDC. <https://www.cdc.gov/folic-acid/data-research/mthfr/index.html>.
96. ^ΔMoll S, Varga E (2015). "Homocysteine and MTHFR Mutations." *Circulation.* **132** (1). doi:[10.1161/CIRCULATIONAHA.114.013311](https://doi.org/10.1161/CIRCULATIONAHA.114.013311).
97. ^ΔBarbagallo M, Veronese N, Dominguez LJ (2021). "Magnesium in Aging, Health and Diseases." *Nutrients.* **13**(2):463. doi:[10.3390/nu13020463](https://doi.org/10.3390/nu13020463).
98. ^ΔKhaidizar FD, Bessho Y, Nakahata Y (2021). "Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process." *Int J Mol Sci.* **22**(7):3709. doi:[10.3390/ijms22073709](https://doi.org/10.3390/ijms22073709).
99. ^ΔCastro-Portuguez R, Sutphin GL (2020). "Kynurenine pathway, NAD⁺ synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan." *Exp Gerontol.* **132**:110841. doi:[10.1016/j.exger.2020.110841](https://doi.org/10.1016/j.exger.2020.110841).
100. ^ΔZhang C, Zhang T, Zou J, Miller CL, Gorkhali R, Yang JY, et al. (2016). "Structural basis for regulation of human calcium-sensing receptor by magnesium ions and an unexpected tryptophan derivative co-agonist." *Sci Adv.* **2**(5):e1600241. doi:[10.1126/sciadv.1600241](https://doi.org/10.1126/sciadv.1600241).
101. ^ΔFerrè S, Hoenderop JG, Bindels RJ (2012). "Sensing mechanisms involved in Ca²⁺ and Mg²⁺ homeostasis." *Kidney Int.* **82**(11):1157–66. doi:[10.1038/ki.2012.179](https://doi.org/10.1038/ki.2012.179).
102. ^ΔEssex M, Millet Pascual-Leone B, Löber U, et al. (2024). "Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19." *npj Biofilms Microbiomes.* **10**:66. doi:[10.1038/s41522-024-00538-0](https://doi.org/10.1038/s41522-024-00538-0).
103. ^ΔBidell MR, Hobbs ALV, Lodise TP (2022). "Gut microbiome health and dysbiosis: A clinical primer." *Pharmacotherapy.* **42**(11):849–857. doi:[10.1002/phar.2731](https://doi.org/10.1002/phar.2731).
104. ^ΔSalazar J, Durán P, Díaz MP, Chacín M, Santeliz R, Mengual E, et al. (2023). "Exploring the Relationship between the Gut Microbiota and Ageing: A Possible Age Modulator." *Int J Environ Res Public Health.* **20**(10):5845. doi:[10.3390/ijerph20105845](https://doi.org/10.3390/ijerph20105845).
105. ^ΔCerqueira N, Brás N, João M, Alexandrino P (2012). "Glycosidases – A Mechanistic Overview." *Carbohydrates – Comprehensive Studies on Glycobiology and Glycotechnology.* doi:[10.5772/52019](https://doi.org/10.5772/52019).
106. ^ΔFerenc K, Sokal-Dembowska A, Helma K, Motyka E, Jarmakiewicz-Czaja S, Filip R (2024). "Modulation of the Gut Microbiota by Nutrition and Its Relationship to Epigenetics." *Int J Mol Sci.* **25**(2):1228. doi:[10.3390/ijms25021228](https://doi.org/10.3390/ijms25021228).
107. ^ΔSchiopu C, Ștefănescu G, Diaconescu S, Bălan GG, Gimiga N, Rusu E, et al. (2022). "Magnesium Orotate and the Microbiome–Gut–Brain Axis Modulation: New Approaches in Psychological Comorbidities of Gastrointestinal Functional Disorders." *Nutrients.* **14**(8):1567. doi:[10.3390/nu14081567](https://doi.org/10.3390/nu14081567).
108. ^ΔHardwick LL, Jones MR, Brautbar N, Lee DB (1991). "Magnesium absorption: mechanisms and the influence of vitamin D, calcium and phosphate." *J Nutr.* **121**(1):13–23. doi:[10.1093/jn/121.1.13](https://doi.org/10.1093/jn/121.1.13).

109. ^a ^bRosanoff A, Dai Q, Shapses SA (2016). "Essential Nutrient Interactions: Does Low or Suboptimal Magnesium Status Interact with Vitamin D and/or Calcium Status?" *Adv Nutr*. 7:25–43. doi:[10.3945/an.115.008631](https://doi.org/10.3945/an.115.008631).
110. ^ΔAshique S, Kumar S, Hussain A, Mishra N, Garg A, Gowda BHJ, et al. (2023). "A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer." *J Health Popul Nutr*. 42(1):74. doi:[10.1186/s41043-023-00423-0](https://doi.org/10.1186/s41043-023-00423-0).
111. ^ΔYang Z, Zhang Y, Gao J, Yang Q, Qu H, Shi J (2024). "Association between dietary magnesium and 10-year risk of a first hard atherosclerotic cardiovascular disease event." *Am J Med Sci*. 368(4):355–360. doi:[10.1016/j.amjms.2024.05.014](https://doi.org/10.1016/j.amjms.2024.05.014).
112. ^ΔDu K, Zheng X, Ma ZT, Lv JY, Jiang WJ, Liu MY (2022). "Association of Circulating Magnesium Levels in Patients With Alzheimer's Disease From 1991 to 2021: A Systematic Review and Meta-Analysis." *Front Aging Neurosci*. 13:799824. doi:[10.3389/fnagi.2021.799824](https://doi.org/10.3389/fnagi.2021.799824).
113. ^ΔDeng X, Song Y, Manson JE, et al. (2013). "Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III." *BMC Med*. 11:187. doi:[10.1186/1741-7015-11-187](https://doi.org/10.1186/1741-7015-11-187).
114. ^ΔCostello RB, Elin RJ, Rosanoff A, Wallace TC, Guerrero-Romero F, Hruby A, Lutsey PL, Nielsen FH, Rodriguez-Moran M, Song Y, et al. (2016). "Perspective: The Case for an Evidence-Based Reference Interval for Serum Magnesium: The Time Has Come." *Adv Nutr*. 7:977–993. doi:[10.3945/an.116.012765](https://doi.org/10.3945/an.116.012765).
115. ^ΔRazzaque MS (2018). "Magnesium: Are We Consuming Enough?" *Nutrients*. 10(12):1863. doi:[10.3390/nu10121863](https://doi.org/10.3390/nu10121863).
116. ^ΔElin RJ (2010). "Assessment of magnesium status for diagnosis and therapy." *Magn Res*. 23(4):S194–8. <https://doi.org/10.1684/mrh.2010.0213>.
117. ^ΔMicke O, Vormann J, Kraus A, Kisters K (2021). "Serum Magnesium: Time for a Standardized and Evidence-Based Reference Range." *Magnetic Resonance*. 34:84–89. [https://www.magnesium-ges.de/Micke et al. 2021.pdf](https://www.magnesium-ges.de/Micke%20et%20al.%202021.pdf).
118. ^ΔRosanoff A, West C, Elin RJ, Micke O, Baniasadi S, Barbagallo M, et al. (2022). "MaGNet Global Magnesium Project (MaGNet). Recommendation on an updated standardization of serum magnesium reference ranges." *Eur J Nutr*. 61(7):3697–3706. doi:[10.1007/s00394-022-02916-w](https://doi.org/10.1007/s00394-022-02916-w).
119. ^ΔWeiss D, Brunk DK, Goodman DA (2018). "Scottsdale Magnesium Study: Absorption, Cellular Uptake, and Clinical Effectiveness of a Timed-Release Magnesium Supplement in a Standard Adult Clinical Population." *J Am Coll Nutr*. 37(4):316–327. doi:[10.1080/07315724.2017.1398686](https://doi.org/10.1080/07315724.2017.1398686).
120. ^ΔHoy MK, Goldman JD (2014). "Calcium intake of the U.S. population: What We Eat in America, NHANES 2009–2010." <https://www.ncbi.nlm.nih.gov/books/NBK589560/>.
121. ^ΔShlisky J, Mandlik R, Askari S, Abrams S, Belizan JM, Bourassa MW, Cormick G, Driller-Colangelo A, Gomes F, Khadilkar A, Owino V, Pettifor JM, Rana ZH, Roth DE, Weaver C (2022). "Calcium deficiency worldwide: prevalence of inadequate intakes and associated health outcomes." *Ann N Y Acad Sci*. 1512(1):10–28. doi:[10.1111/nyas.14758](https://doi.org/10.1111/nyas.14758).
122. ^ΔGuerrero-Romero F, Mercado M, Rodriguez-Moran M, et al. (2022). "Magnesium-to-Calcium Ratio and Mortality from COVID-19." *Nutrients*. 14(9):1686. doi:[10.3390/nu14091686](https://doi.org/10.3390/nu14091686).
123. ^ΔLa Carrubba A, Veronese N, Di Bella G, Cusumano C, Di Prazza A, Ciriminna S, et al. (2023). "Prognostic Value of Magnesium in COVID-19: Findings from the COMEPA Study." *Nutrients*. 15(4):830. doi:[10.3390/nu15040830](https://doi.org/10.3390/nu15040830).

124. [△]Fan L, Zhu X, Zheng Y, Zhang W, Seidner DL, Ness R, Murff HJ, Yu C, Huang X, Shrubsole MJ, Hou L, Dai Q (2021). "Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2)." *Nutrition*. **89**:111340. doi:[10.1016/j.nut.2021.111340](https://doi.org/10.1016/j.nut.2021.111340).
125. [△]Balnis J, Madrid A, Drake LA, Vancavage R, Tiwari A, Patel VJ, et al. (2024). "Blood DNA methylation in post-acute sequelae of COVID-19 (PASC): a prospective cohort study." *EBioMedicine*. **106**:105251. doi:[10.1016/j.ebiom.2024.105251](https://doi.org/10.1016/j.ebiom.2024.105251).
126. [△]Ponti G, Pastorino L, Manfredini M, Ozben T, Oliva G, Kaleci S, Iannella R, Tomasi A (2021). "COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence." *J Clin Lab Anal*. **35**(7):e23798. doi:[10.1002/jcla.23798](https://doi.org/10.1002/jcla.23798).
127. [△]^bAbraham GE, Schwartz UD, Lubran MM (1981). "Effect of vitamin B-6 on plasma and red blood cell magnesium levels in premenopausal women." *Ann Clin Lab Sci*. **11**:333–336. PMID [7271227](https://pubmed.ncbi.nlm.nih.gov/7271227/).
128. [△]^bBoylan LM, Spallholz JE (1990). "In vitro evidence for a relationship between magnesium and vitamin B-6." *Magn Res*. **3**:79–85. PMID [2133627](https://pubmed.ncbi.nlm.nih.gov/2133627/).
129. [△]Noah L, Pickering G, Dubray C, Mazur A, Hitier S, Pouteau E (2020). "Effect of vitamin B6 supplementation, in combination with magnesium, on severe stress and magnesium status: Secondary analysis from an RCT." *Proceedings of the Nutrition Society*. **79**(OCE2):E491. doi:[10.1017/S0029665120004395](https://doi.org/10.1017/S0029665120004395).
130. [△]Pouteau E, Kabir-Ahmadi M, Noah L, Mazur A, Dye L, Hellhammer J, Pickering G, Dubray C (2018). "Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial." *PLoS One*. **13**(12):e0208454. doi:[10.1371/journal.pone.0208454](https://doi.org/10.1371/journal.pone.0208454).
131. [△]Eisinger J, Dagorn J (1986). "Vitamin B6 and magnesium." *Magnesium*. **5**(1):27–32. PMID [3959594](https://pubmed.ncbi.nlm.nih.gov/3959594/).
132. [△]Planells E, Lerma A, Sánchez-Morito N, Aranda P, Llopis J (1997). "Effect of magnesium deficiency on vitamin B2 and B6 status in the rat." *J Am Coll Nutr*. **16**(4):352–6. doi:[10.1080/07315724.1997.10718697](https://doi.org/10.1080/07315724.1997.10718697).
133. [△]Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM (2017). "The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function." *Toxicol In Vitro*. **44**:206–212. doi:[10.1016/j.tiv.2017.07.009](https://doi.org/10.1016/j.tiv.2017.07.009).
134. [△]Mikkelsen K, Apostolopoulos V (2018). "B Vitamins and Ageing." *Subcell Biochem*. **90**:451–470. doi:[10.1007/978-981-13-2835-0_15](https://doi.org/10.1007/978-981-13-2835-0_15).
135. [△]Stoff R, Wolf Y, Boursi B (2023). "Fecal Microbiota Transplantation as a Cancer Therapeutic." *Cancer J*. **29**(2):102–108. doi:[10.1097/PP0.0000000000000651](https://doi.org/10.1097/PP0.0000000000000651).
136. [△]Liu X, Liu M, Zhao M, Li P, Gao C, Fan X, Cai G, Lu Q, Chen X (2023). "Fecal microbiota transplantation for the management of autoimmune diseases: Potential mechanisms and challenges." *J Autoimmun*. **141**:103109. doi:[10.1016/j.jaut.2023.103109](https://doi.org/10.1016/j.jaut.2023.103109).
137. [△]Wang H, Yang F, Zhang S, et al. (2021). "Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation." *npj Parkinsons Dis*. **7**:70. doi:[10.1038/s41531-021-00213-7](https://doi.org/10.1038/s41531-021-00213-7).
138. [△]Costello RB, Rosanoff A, Dai Q, Saldanha LG, Potischman NA (2021). "Perspective: Characterization of Dietary Supplements Containing Calcium and Magnesium and Their Respective Ratio-Is a Rising Ratio a Cause for Concern?" *Adv Nutr*. **12**(2):291–297. doi:[10.1093/advances/nmaa160](https://doi.org/10.1093/advances/nmaa160).

139. [△]Matsuoka H (2005). "Aldosterone and Magnesium." *Clinical Calcium*. 15:187–191. PMID [15692156](#).
140. [△]Taylor K, Tripathi AK, Jones EB (2022). "Adult Dehydration." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID [32310416](#).
141. [△]Baffour-Awuah B, Man M, Goessler KF, et al. (2024). "Effect of exercise training on the renin–angiotensin–aldosterone system: a meta–analysis." *J Hum Hypertens*. 38:89–101. doi:[10.1038/s41371-023-00872-4](#).
142. [△]van der Heijden CDCC, Ter Horst R, van den Munckhof ICL, Schraa K, de Graaf J, Joosten LAB, et al. (2020). "Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity." *J Clin Endocrinol Metab*. 105(8):2719–31. doi:[10.1210/clinem/dgaa356](#).
143. [△]Gomez-Sanchez E, Gomez-Sanchez CE (2014). "The multifaceted mineralocorticoid receptor." *Compr Physiol*. 4(3):965–94. doi:[10.1002/cphy.c130044](#).
144. [△]Dmitrieva NI, Gagarin A, Liu D, Wu CO, Boehm M (2023). "Middle-age high normal serum sodium as a risk factor for accelerated biological aging, chronic diseases, and premature mortality." *EBioMedicine*. 87:104404. doi:[10.1016/j.ebiom.2022.104404](#).
145. [△]Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, Pinotti L, Maier JA, Cazzola R (2021). "Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes." *Nutrients*. 13(2):320. doi:[10.3390/nu13020320](#).
146. [△]Dan J, Yang J, Liu Y, Xiao A, Liu L (2015). "Roles for Histone Acetylation in Regulation of Telomere Elongation and Two-cell State in Mouse ES Cells." *J Cell Physiol*. 230(10):2337–44. doi:[10.1002/jcp.24980](#).
147. [△]Jones G, Prosser DE, Kaufmann M (2014). "Cytochrome P450-mediated metabolism of vitamin D." *J Lipid Res*. 55(1):13–31. doi:[10.1194/jlr.R031534](#).
148. [△]Chen J, Zhao KN, Chen C (2014). "The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis." *Ann Transl Med*. 2(1):7. doi:[10.3978/j.issn.2305-5839.2013.03.02](#).
149. [△]Pikuleva IA (2008). "Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering." *Expert Opin Drug Metab Toxicol*. 4(11):1403–14. doi:[10.1517/17425255.4.11.1403](#).
150. [△]Pludowski P, Holick MF, Pilz S, et al. (2013). "Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence." *Autoimmunity Reviews*. 12(10):976–989. doi:[10.1016/j.autrev.2013.02.004](#).
151. [△]Laborde S, Mosley E, Thayer JF (2017). "Heart Rate Variability and Cardiac Vagal Tone in Psychophysiological Research – Recommendations for Experiment Planning, Data Analysis, and Data Reporting." *Front Psychol*. 8:213. doi:[10.3389/fpsyg.2017.00213](#).
152. [△]Shanmukha KD, Paluvai H, Lomada SK, Gokara M, Kalangi SK (2023). "Histone deacetylase (HDACs) inhibitors: Clinical applications." *Prog Mol Biol Transl Sci*. 198:119–152. doi:[10.1016/bs.pmbts.2023.02.011](#).
153. [△]Banik D, Moufarrij S, Villagra A (2019). "Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy." *International Journal of Molecular Sciences*. 20(9):2241. doi:[10.3390/ijms20092241](#).
154. [△]Guha S, Jagadeesan Y, Pandey MM, Mittal A, Chitkara D (2024). "Targeting the epigenome with advanced delivery strategies for epigenetic modulators." *Bioengineering & Translational Medicine*. 10(1). doi:[10.1002/btm2.10710](#).
155. [△]Zhang S, Kiarasi F (2024). "Therapeutic effects of resveratrol on epigenetic mechanisms in age-related diseases: A comprehensive review." *Phytother Res*. 38(5):23

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.